Are You at Risk for Myasthenia Gravis? What to Know

Myasthenia gravis (MG) is rare enough that most people never think about their personal risk at all - until a symptom or a family diagnosis brings the question up suddenly. If that's what brought you here, this article walks through what current research actually says about who is more likely to develop MG, what genuinely raises risk, and - just as importantly - what doesn't.

How Common Is Myasthenia Gravis, Really?

Before getting into individual risk factors, it helps to have a sense of scale. Myasthenia gravis prevalence sits at roughly 150 to 200 cases per million people - in other words, somewhere between 1 in 5,000 and 1 in 6,700 people. It is genuinely rare. Most people, even those with one or two of the risk factors below, will never develop it. But "rare" and "random" are not the same thing - certain factors do meaningfully shift the odds.

Age and Sex: The Clearest Pattern in the Data

If there is one risk pattern that shows up consistently across studies worldwide, it's this one - and it's a bit more nuanced than a simple "more common in women" statement.

Myasthenia gravis follows a bimodal age and sex pattern: it tends to affect younger women (under 40) and older men (over 60) more than other age-sex combinations. This isn't a minor statistical quirk - it's significant enough that researchers now treat early-onset MG (before age 50) and late-onset MG (50 and older) as genuinely distinct disease subgroups, with different sex ratios, different genetic associations, and even different immune cell signatures.

A 2025 study using deep immune profiling found that early-onset and late-onset MG differ at the cellular level - late-onset MG showed lower frequencies of certain T cell populations, suggesting a pattern of enhanced immune senescence (age-related immune system decline) that simply isn't part of the picture in younger-onset disease. In other words, MG in a 30-year-old woman and MG in a 70-year-old man may be driven by meaningfully different underlying processes, even though both ultimately produce the same antibody-mediated attack on the neuromuscular junction.

Genetics: What Recent Research Has Found

For a long time, MG's genetic contribution was understood only in broad strokes. That changed substantially with a major 2024 study, and it's worth understanding both what it found and what it didn't.

The 2024 Genome-Wide Study

A large genome-wide meta-analysis published in Nature Communications analyzed genetic data from 5,708 people with MG and over 658,000 people without it, across European-ancestry cohorts, with an independent replication study through 23andMe. The researchers identified 12 independent genetic risk locations across 11 regions of the genome that reach genome-wide statistical significance for association with MG.

Critically, the study found that two of these genetic signals were specifically associated with early-onset MG and four were specifically associated with late-onset MG - direct genetic confirmation that these really are somewhat distinct conditions sharing a final common pathway, not just an arbitrary age cutoff.

The strongest single genetic signal, as in most prior MG genetics research, sits in the HLA (human leukocyte antigen) region on chromosome 6 - the same family of genes that governs how the immune system distinguishes "self" from "foreign." The study identified HLA-B*08:01 as the top risk-associated allele, while a different HLA variant, HLA-DQB1*03, appeared to have a protective effect - lowering risk rather than raising it. Interestingly, the effect sizes for several HLA associations actually reversed direction between early-onset and late-onset disease, reinforcing that age of onset isn't incidental to the underlying genetics.

What a "Polygenic Risk Score" Can and Can't Tell You

The same study built a polygenic risk score - a single number combining the effect of many genetic variants - and tested whether it could predict who actually develops MG. The result: the polygenic risk score significantly predicted MG status in an independent test group, but explained only 4.21% of the overall variation in who develops the disease.

That number matters more than it might first appear. It means genetics is real and measurable - but it is nowhere close to the whole story. The vast majority of why one person develops MG and another doesn't remains unexplained by currently known genetic variants alone, which strongly implies that non-genetic factors (environmental triggers, immune history, and simple chance) play a substantial role as well.

NLRP3 and the Inflammasome

Beyond the broad genome-wide signals, more targeted research has looked at specific genes involved in immune regulation. Variants in the NLRP3 gene - which encodes a key component of the inflammasome, a cellular complex involved in triggering inflammation - are significantly associated with MG risk, with one specific genetic variant (the rs3806265 C allele) showing a notably increased association with developing the disease. This adds to a growing picture in which MG risk isn't governed by a single gene, but by the cumulative pull of many genes involved in immune regulation, tolerance, and inflammation.

Should You Get Genetic Testing?

Based on current evidence, routine genetic testing to predict individual MG risk is not standard practice and wouldn't currently provide a clinically meaningful answer - the polygenic risk score explaining just over 4% of variation is genuinely useful for population-level research, but it isn't precise enough to tell any one person their individual odds. If you have a strong family history of MG or other autoimmune disease and specific concerns, that conversation belongs with a genetic counselor or neurologist who can put it in proper clinical context, not with a do-it-yourself genetic test.

Having Another Autoimmune Disease

This is one of the more practically useful risk patterns to know about, because unlike genetics, it's something you may already know about yourself.

Autoimmune thyroid disease is a recognized comorbidity in myasthenia gravis, and having one autoimmune condition generally does raise the likelihood of developing a second one - a pattern called autoimmune comorbidity or polyautoimmunity, which isn't unique to MG but is well documented within it.

A 2025 study looking specifically at MG patients with coexisting autoimmune disease found that these patients had a higher frequency of autoimmune disease among their own family members compared to MG patients without a second autoimmune condition, and that autoimmune comorbidities were more common in female patients overall. Importantly, the same study found that having a second autoimmune disease did not significantly change the type of MG antibody present (AChR, MuSK, or seronegative), the way the disease initially presented, or - reassuringly - the overall prognosis and severity outcomes. In other words: having another autoimmune disease appears to raise the odds of also developing MG, but does not appear to make MG itself more severe once it occurs.

Conditions reported alongside MG in the literature include autoimmune thyroid disease (most common), and rarer documented co-occurrences such as lichen planus - a 2024 systematic review found only 13 prior cases of MG and lichen planus reported together since 1971, underscoring how uncommon most specific autoimmune pairings actually are, even when the general pattern of autoimmune clustering is real.

Thymoma: A Distinct and Important Risk Factor

The thymus gland's connection to MG is well-established, but it's worth separating two related but distinct ideas: ordinary thymic involvement (common in many MG cases) versus thymoma specifically (a tumor of the thymus), which represents a more particular risk category.

Thymoma - a tumor arising in the thymus gland - is a well-documented association with MG, though researchers are clear that the exact causal relationship - whether the thymoma causes MG, or both arise from a shared underlying process - is still not fully understood. What is established is that thymoma-associated MG (TAMG) is now recognized as a distinct disease subtype with its own genetic and immunological features, separate from typical early- or late-onset disease.

This distinction matters clinically: a Scientific Reports study examining factors associated with increased severity of generalized MG found that thymoma or thymic hyperplasia was independently associated with greater disease severity, alongside older age at onset, female sex, and higher acetylcholine receptor antibody titers. This is part of why chest imaging to screen for thymoma is a standard part of the diagnostic workup for anyone newly diagnosed with AChR-antibody-positive MG.

Pregnancy: A Risk Window Worth Knowing About

For women who already have myasthenia gravis, or who are at elevated risk based on the patterns described above, pregnancy and the postpartum period represent a specific window of heightened vulnerability worth understanding in advance.

A study of 113 women with MG and a history of pregnancy, conducted at Huashan Hospital, found that 46% experienced at least one MG relapse during pregnancy or the postpartum period, with relapses clustering heavily in two specific windows: the first trimester of pregnancy and the three months immediately following delivery. Roughly 45% of relapses occurred in each of those two windows respectively, with far fewer occurring in the second and third trimesters in between. This U-shaped pattern - risk concentrated at the very start of pregnancy and again right after delivery - reflects the dramatic immune system shifts that occur at both ends of pregnancy, and is genuinely useful information for anyone with MG planning a pregnancy, since it allows for proactive monitoring during the specific windows where relapse risk is highest, rather than treating the entire nine months as uniformly risky.

What Does NOT Appear to Meaningfully Raise Risk

It's just as useful to know what current evidence does not support as a major risk factor, since misinformation here can cause unnecessary worry.

There is currently no strong evidence that diet, ordinary physical activity, vaccination, or common over-the-counter medications cause MG to develop in someone who didn't already have the underlying autoimmune predisposition. This is distinct from the well-established fact that certain medications can worsen symptoms in someone who already has MG - that's a separate clinical issue from causing the disease to begin with, and one worth discussing separately with a physician if relevant to you.

Researchers studying environmental exposures in the same genome-wide study mentioned earlier did look for associations with specific drug categories and found one intriguing signal involving ectoparasiticides (used against external parasites like lice or mites), but the researchers themselves noted this finding did not survive correction for multiple statistical testing and should be treated as a preliminary, unconfirmed signal rather than an established risk factor.

Putting It All Together: A Realistic Risk Picture

If you're trying to gauge your own personal risk picture, here's a reasonable synthesis of what current research supports:

Risk is somewhat elevated if you are:

• A woman under 40, or a man over 60 (the two peak-incidence groups)
• Already living with another autoimmune condition, particularly autoimmune thyroid disease
• Found to have a thymoma on imaging done for any reason
• Someone with a first-degree relative who has MG or another autoimmune disease, though this confers a modest, not dramatic, increase in risk

Risk does not appear to be meaningfully elevated by:

• Diet, exercise habits, or general lifestyle factors
• Routine vaccination
• Having no family history at all - the large majority of MG cases occur in people without any known family history of the disease

The most honest overall statement current science supports: MG arises from a combination of genetic predisposition (now understood across at least 11 confirmed genomic regions, but explaining only a modest fraction of overall risk) and likely environmental or immunological triggers that remain incompletely understood. If you fall into one or more of the elevated-risk categories above, that is useful context - not a prediction, and certainly not a reason for alarm. The disease remains genuinely rare even within these higher-risk groups.

This article is for educational purposes only and does not constitute medical advice. If you have concerns about your personal risk for myasthenia gravis based on family history, existing autoimmune disease, or new symptoms, please consult a qualified neurologist for individualized evaluation.